Skip to main content

Regulatory Effects of Peptides from the Pro and Catalytic Domains of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) on Low-Density Lipoprotein Receptor (LDL-R)

Buy Article:

$63.00 plus tax (Refund Policy)


Background: Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) is a Proteinase K subtype of mammalian subtilases collectively called PCSKs. PCSK9 upregulates plasma-cholesterol level by degrading low-density lipoprotein receptor (LDL-R). As a result, PCSK9 is a major target for intervention of hypercholesterolemia and in this regard PCSK9- inhibitors may find useful therapeutic and biochemical applications

Objective: Our objective is to develop short peptide based PCSK9 inhibitors from its own pro and/or catalytic domains.

Results: Using human (h) hepatic HepG2 and Huh7 cells we showed that the acidic N-terminal hPCSK931-60, 31-40 and the mid-basic hPCSK991-120 peptides derived from hPCSK9-prodomain significantly enhanced LDL-R level without altering PCSK9 content. Moreover, the physiologically relevant phoshpho-Ser47 and sulpho-Y38 containing hPCSK931-60 peptides diminished LDL-R level suggesting that such posttranslational modifications in the prodomain lead to gain of PCSK9- functional activity. These modifications are thus expected to lead to even higher level of plasma cholesterol. As expected, addition of purified recombinant-PCSK9 to the culture medium decreased LDL-R level which can be restored back by exogenous addition of hPCSK931-40, 31-60 or 91-120 peptides. Using a series of truncated peptides, we identified the most potent LDL-R promoting activity to reside within the prodomain sequence hPCSK931-37. Two catalytic domain peptides hPCSK9181-200 and hPCSK9368-390, containing proposed LDL-R interacting sites have been shown to diminish LDL-R level.

Conclusion: Our study concludes that specific peptides from pro- and catalytic domains of hPCSK9 can regulate LDL-R in cell based assay and may be useful for development of novel therapeutics for cholesterol regulation.

Keywords: Cholesterol regulation; Low density lipoprotein receptor; PCSK9 inhibitors; Proprotein Convertase Subtilisin/Kexin9 (PCSK9)

Document Type: Research Article


Affiliations: Chronic Diseases Program, Regional Protein Chemistry Center, Ottawa Hospital Research Institute, U Ottawa, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.

Publication date: 2010-07-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more